Sulfadiazine sodium injection is a sulfonamide antibacterial drug, which can be used for the treatment of meningitis caused by sensitive Neisseria meningitidis, and can also be used for the treatment of acute bronchitis and mild pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae and other streptococcus bacteria which are sensitive to it. Sulfadiazine sodium injection, the main component of which is sulfadiazine sodium, is a moderately effective sulfonamide antibacterial drug, with antibacterial effects on many gram-positive and negative bacteria, and is mainly used in the treatment of meningitis caused by sensitive Neisseria meningitidis and acute bronchitis and mild pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae and other streptococci sensitive to it. In addition, this product is also active in vitro against Nucella sativa, Plasmodium and Toxoplasma gondii, so it can also be used for the treatment of Nucella sativa and the treatment of toxoplasmosis caused by Toxoplasma gondii by combining with ethylpyrimethamine, and it can be used as an adjuvant for the treatment of chloroquine-resistant falciparum malaria. The use of this product may be headache, fatigue, nausea, vomiting, loss of appetite, diarrhea and other minor discomforts, but also may cause hepatic and renal damage, hyperbilirubinemia, hemolytic anemia, hemoglobinuria and allergic reactions, its serious adverse reactions, although rare, but can be fatal, so the treatment should be closely observed, when the skin rash or other reactions to the appearance of the early signs of the drug should be immediately discontinued. It should be contraindicated in pregnant women, lactating women, infants less than 2 months old and those with severe hepatic or renal dysfunction, or allergic to sulfonamides, etc. Its use should be carried out in a medical institution by a professional caregiver on medical advice.